Allergan to buy MAP Pharmaceuticals
Allergan Inc. plans to acquire MAP Pharmaceuticals Inc. in a deal valued at about $958 million. The drug companies said Tuesday evening that the transaction will be done through a cash tender offer followed by a second-step merger. The per-share cash offer price represents a 60% premium over